KOBAYASHI PHARM
There is no Profile data available for KOY.MU.
KOBAYASHI PHARM (KOY) - Total Assets
Latest total assets as of June 2025: €260.71 Billion EUR
Based on the latest financial reports, KOBAYASHI PHARM (KOY) holds total assets worth €260.71 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
KOBAYASHI PHARM - Total Assets Trend (2017–2024)
This chart illustrates how KOBAYASHI PHARM’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
KOBAYASHI PHARM - Asset Composition Analysis
Current Asset Composition (December 2024)
KOBAYASHI PHARM's total assets of €260.71 Billion consist of 54.4% current assets and 45.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 19.2% |
| Accounts Receivable | €49.44 Billion | 18.6% |
| Inventory | €24.16 Billion | 9.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €11.41 Billion | 4.3% |
| Goodwill | €9.26 Billion | 3.5% |
Asset Composition Trend (2017–2024)
This chart illustrates how KOBAYASHI PHARM's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: KOBAYASHI PHARM's current assets represent 54.4% of total assets in 2024, a decrease from 65.1% in 2017.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2024, down from 29.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 1.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 18.6% of total assets.
KOBAYASHI PHARM Competitors by Total Assets
Key competitors of KOBAYASHI PHARM based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
KOBAYASHI PHARM - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - KOBAYASHI PHARM generates 0.62x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, KOBAYASHI PHARM generates $ 3.79 in net profit.
KOBAYASHI PHARM - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 2.88 | 3.65 |
| Quick Ratio | 2.26 | 2.21 | 3.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €89.47 Billion | € 86.42 Billion | € 116.07 Billion |
KOBAYASHI PHARM - Advanced Valuation Insights
This section examines the relationship between KOBAYASHI PHARM's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -0.8% |
| Total Assets | €265.37 Billion |
| Market Capitalization | $284.90K USD |
Valuation Analysis
Below Book Valuation: The market values KOBAYASHI PHARM's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: KOBAYASHI PHARM's assets decreased by 0.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for KOBAYASHI PHARM (2017–2024)
The table below shows the annual total assets of KOBAYASHI PHARM from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €265.37 Billion | -0.79% |
| 2023-12-31 | €267.47 Billion | +4.55% |
| 2022-12-31 | €255.83 Billion | +1.30% |
| 2021-12-31 | €252.55 Billion | +5.95% |
| 2020-12-31 | €238.37 Billion | +2.13% |
| 2019-12-31 | €233.40 Billion | +1.04% |
| 2018-12-31 | €230.99 Billion | +5.56% |
| 2017-12-31 | €218.83 Billion | -- |